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ABSTRACT
Whole-body UV-B phototherapy has been used for the treatment of graft-versus-host disease (GVHD) of
the skin and has systemic immunosuppressive and tolerogenic effects. We hypothesized that whole-body
UV-B therapy would improve donor engraftment and decrease the incidence and severity of GVHD that
is associated with decreased intensity allogeneic hematopoietic stem cell transplantation. This study tested
the feasibility of using UV-B phototherapy that was initiated before grafting and continued until engraft-
ment to determine its effect on transplantation outcome. Eight patients (median age, 55.5 years; range,
32-65 years) with hematologic malignancies were included. Allogeneic peripheral blood stem cells were
obtained from matched related (n  5) or matched unrelated (n  3) donors. Conditioning regimen was
fludarabine 30 mg/m2 intravenously for 5 days, cyclophosphamide 1 g/m2/d intravenously for 2 days, and
equine antithymocyte globulin 30 mg/kg/d for 2 days. GVHD prophylaxis included cyclosporine, meth-
ylprednisolone, and escalating doses of narrowband UV-B (311 nm) according to skin tolerance, 3 days a
week, from 10 days before to 28 days after transplantation. The conditioning regimen and the UV-B
therapy were well tolerated. Two patients received all 14 prescribed UV-B treatments (cumulative doses
of 2000 and 3260 mJ/cm2, respectively) and 6 patients received 8 to 13 treatments with a cumulative dose
range of 528-3465 mJ/cm2. There was a rapid decrease in epidermal CD1a cells by day of transplantation.
Myeloid engraftment was rapid. One patient had secondary engraftment failure at 3 months and another
had mixed chimerism at day 100. Seven of 8 patients developed severe acute GVHD (grade III, n  5; grade
IV, n  2). Six had skin involvement, 5 had gastrointestinal involvement, and 1 had liver involvement. Four
patients died (2 from sepsis, 1 from acute GVHD, and 1 from chronic GVHD). Four patients are alive
(130-287 days), 3 with extensive chronic GVHD. We conclude that extended peritransplant UV-B therapy
at the standard minimally erythemogenic dose is detrimental to the outcome of allogeneic stem cell
transplantation. It is unclear how UV-B at this immunsuppressive dose might have altered skin and
systemic cytokine and immune cell compositions in the host and increased GVHD- and treatment-related
mortalities. Different UV-B dose and schedules should be further explored. However, although other
phototherapeutic modalities may be effective against GVHD, extended UV-B therapy should not be used
during early phases of decreased conditioning allogeneic transplantation.
© 2006 American Society for Blood and Marrow Transplantation
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6NTRODUCTION
Graft-versus-host disease (GVHD) is a major con-
ributor to the morbidity and mortality associated
ith allogeneic bone marrow transplantation [1]. Even
hen HLA-identical siblings are the source of hema-
opoietic stem cells (HSCs) for infusion, the likeli-
ood of developing clinically signiﬁcant acute and
hronic GVHD approaches 35% and 50%, respec-
ively [2,3]. New therapeutic modalities are being in-
estigated for the prevention and treatment of GVHD
4]. Phototherapy, ﬁrst discovered by ancient Egyp-
ians [5], has numerous medical uses and shown to
roduce various immunomodulatory effects [6]. Pso-
alen plus UV-A (320-400 nm), broadband UV-B
290-320 nm), narrowband UV-B (311 nm), and long-
ave UV-A (340-400 nm) are used in the treatment of
arious inﬂammatory skin conditions. Phototherapy
lters antigen presentation and T-cell responsiveness
n skin, although speciﬁc effects vary by the host
ondition, exposure duration, dose, and other vari-
bles. Like classic phototherapy, extracorporeal pho-
opheresis alters T-cell function and antigen presen-
ation [7]. Direct UV-B irradiation of bone marrow
nd spleen cell allografts in mice has been shown to
bolish alloreactive responses that normally cause
VHD. Broadband UV-B irradiation of bone marrow
ermits transplantation across a major histocompati-
ility barriers [8].
Although HSC transplantation is curative treat-
ent for some patients with hematologic malignan-
ies, associated toxicities with ablative therapy have
imited treatment to younger, medically ﬁt patients
9]. Reduced intensity transplant regimens decrease
arly mortality but engraftment failure and GVHD
emain major obstacles [10]. We hypothesized that
hole-body UV-B therapy, due to its effects on im-
une system, particularly the antigen presenting cells
f the skin, would decrease the incidence and severity
f GVHD. We conducted a pilot feasibility trial of
V-B phototherapy as part of a conditioning regimen
nd as part of early GVHD prophylaxis in patients
ho were recommended to receive nonmyeloablative
llogeneic HSC transplantation.
ETHODS
Patients in need of allogeneic HSC transplanta-
ion for hematologic malignancy and were 55 years
f age, had received a previous autologous or alloge-
eic transplantation with myeloablative conditioning,
r had comorbid conditions that precluded their eli-
ibility for myeloablative transplantation were invited
o participate in the protocol. Consent procedure in-
luded review of potential risks and beneﬁts with the
ransplant physician and the protocol and consent
rocedures were approved by the instutitional review b
66oard for human investigation of University Hospitals
f Cleveland (Cleveland, OH). Patients and donors
ere matched for all HLA-A, -B, and -DR antigens by
igh-resolution assay.
Sibling donors were treated with granulocyte col-
ny-stimulating factor (Neupogen, Amgen Thousand
aks, CA) that was administered by subcutaneous
njection at a dose of 10 g/kg/d, based on actual body
eight, for 5 to 7 days. Peripheral blood apheresis
ommenced on day 5 and was continued on days 6 and
, if necessary, to reach the target cell dose of 5  106
D34/kg recipient weight. If 10  106/kg CD34
ells/kg were obtained, a maximum of 10  106/kg
D34 cells/kg was used for transplantation. Matched,
nrelated donors were treated according to National
arrow Donor Program guidelines and regulations. A
inimum of 5  106/kg CD34cells/kg was requested.
onditioning Regimen
Transplant day was designated as T-0. Fludara-
ine 30 mg/m2/d  5 days (days 8 to 4), cyclo-
hosphamide 1 g/m2/d  2 days (days 3 to 2), and
ntithymocyte globulin 30 mg/kg/d 2 days (days2
o 1) were given intravenously. Narrowband UV-B
hototherapy was administered between T-10 and
28, 3 days a week,1 day apart. In total, 14 UV-B
reatments were scheduled. Prophylaxes against candida
ith ﬂuconazole, pneumocystis with trimethoprim-sul-
amethoxazole, and herpes simplex and varicella zoster
irus with acyclovir were used routinely. GVHD pro-
hylaxis included methylprednisolone 1 mg/kg/d on
ays T5 to T15 and cyclosporine days on days T-1
o T100 followed by a taper in the absence of
VHD. Toxicity was graded according to the criteria
f the NCI-CTC.
kin Biopsies National Cancer Institute Common
oxicity Criteria
All patients underwent skin biopsy before UV-B
herapy. This was performed by using a 4-mm cuta-
eous punch after local lidocaine anesthesia. Tissue
ample was placed in formalin and embedded in par-
fﬁn for routine histologic analysis. Skin biopsy was
epeated after transplantation, if GVHD was sus-
ected.
D1a Immunostaining
Tissue sections were cut at 3 m onto electrostat-
cally charged Plus slides and dried in a 60°C oven for
hour. Slides were deparafﬁnized with 2 changes of
ylene and hydrated through graded alcohols to water.
ext, slides were placed in a 3% H2O2/H2O bath for
0 minutes to quench endogenous peroxide within the
issue. After a rinse in H2O, slides were subjected to
igh heat epitope enhancement in 10 mM citrate
uffer, pH 6.0. After a brief cool-down period, slides
w
A
p
m
C
b
s
3
i
d
s
a
l
I
p
d
m
P
(
w
r
i
p
b
a
t
t
n
(
t
t
w
a
t
h
r
e
s
T
f
g
b
d
M
t
b
W
s
w
i
k
d
w
p
s
w
S
t
a
r
G
a
t
i
a
r
e
b
v
R
P
(
p
m
J
w
a
o
p
r
a
w
F
a
i
UV-B in Allogeneic Transplantation
Bere rinsed in running H2O and placed on a Dako
utoimmunostainer (Dako, Carpenteria, CA). The
rimary antibody employed was a commercially available
onolonal CD1a from Immunotech (a Beckman-
oulter Company, Brea, CA). Detection was achieved
y using standard horseradish peroxidase-labeled
treptavidin-biotin (LSAB2; Dako) technology using
-3-diaminobenzidine as the chromogen and resulting
n a brown-black color change at sites of antigen
eposition. Slides were then rinsed in H2O, counter-
tained in Gills 3 hematoxylin, blued in ammonia H2O
nd dehydrated back through graded alcohols to xy-
ene, and coverslipped. Quantiﬁcation was done using
mage Pro Plus analysis, which calculates the area of
ositively-stained cells. Percent positive staining was
etermined in 10 20 ﬁelds per biopsy section and
eans  1 SD were used to generate Figure 1.
hototherapy
A full-body narrowband UV-B light box unit
NUV-B 311, National Biologics, Twinsburg, Ohio)
as used for phototherapy. Narrowband UV-B emits
adiation within 311-313 nm and does not require
ngestion of a photosensitizer drug for activity. Com-
ared with broadband UV-B (290-320 nm), narrow-
and UV-B has a better skin penetration. The initial
nd incremental UV-B dose was determined based on
he Fitzpatrick skin phototype (ie, based on the pa-
ient’s inherent capacity to burn or tan in response to
atural sunlight) and the minimum erythema dose
MED) was determined before therapy. To determine
he MED, a template with 8 1-cm holes was taped on
he patient’s lower back. The erect patient was placed
ithin the UV-B light box with only the lower back
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igure 1. CD1a cell density in skin of patients (P) at baseline and
fter the ﬁrst week of UV-B therapy at T-0 (day of stem cell
nfusion). T-7, 7 days before stem cell infusion.rea exposed, and test doses were given as a series of 4
B & M Timed exposures over a few minutes. Approximately 24
ours later, erythema was evaluated. The MED cor-
esponded to the lowest dose of UV-B that was able to
licit a pink erythema with well-deﬁned borders. The
tarting dose of UV-B was set at 70% of the MED.
his dose was increased for subsequent treatments as
ollows: 20-40% if tolerance to the previous dose was
ood, 10-20% if the patient observed a transient sun-
urn reaction, and 0% if the sunburn reaction lasted1
ay. UV-B was adiministered 3 days a week (typically
onday-Wednesday-Friday). Before treatment pa-
ients applied a moisturizer, Vaseline lotion (Green-
rough-Ponds, Greenwich, CT), all over the body.
hile in the UV-B light box, the patient’s eyes were
hielded with UV-protective goggles and genitals
ere covered with clothing. For patients with signif-
cant sun damage on the face (e.g., history of actinic
eratoses), the head also was covered with a pillowcase
uring UV-B exposure. No special sun precautions
ere used after UV-B treatment because no systemic
hotosensitizer (e.g., methoxypsoralen) was used. If
essions were missed due to toxicity, dose decrements
ere made to prevent phototoxicity.
tatistical Analysis
The Simon MinMax 2-stage design was used for
his study [11]. On the assumption of improvement of
cute GVHD rate from 60% to 35%, 9 patients were
equired at the ﬁrst stage. If 6 patients had acute
VHD, then the trial would stop early; otherwise, 10
dditional patients would be enrolled at stage 2. If the
rue acute GVHD rate was 60%, then the probabil-
ty of accepting UV-B therapy was 0.1. If the true
cute GVHD rate was 35%, then the probability of
ejecting UV-B therapy was 0.2. Acute GVHD was
stimated based on the number of cases by using a
inomial distribution theory and its conﬁdence inter-
als was estimated with the Wilson method [12].
ESULTS
atient Characteristics
Eight patients with hematologic malignancies
acute myeloid leukemia, n  2; non-Hodgkin lym-
homa, n  2; Hodgkin disease, n  2; multiple
yeloma, n  2) were enrolled in this study between
anuary 2004 and June 2004 (Table 1). Median age
as 55.5 years (range, 32-65). Four patients had an
utograft that previously failed and 2 patients previ-
usly underwent autologous stem cell mobilization
rocedures that failed. The graft source was matched
elated (n  5) or matched unrelated (n  3) donor
llogeneic peripheral blood stem cells. All donors
ere male, with a median age of 59 years (range,
6-67).
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6ffects of UV-B Therapy
The conditioning regimen and the UV-B therapy
ere well tolerated. Patients were able to stand in the
ight box without much discomfort for the duration of
ach session. Patients observed some post-treatment
rythema, which was expected. Occasionally, a mild
ymptomatic sunburn reaction occurred. Two patients
eceived all 14 prescribed UV-B treatments (cummu-
ative doses, 2000 and 3260 mJ/cm2, respectively) and
patient received 13 treatments, 2 received 12, 1
eceived 11, 1 received 10, and 1 received 8, with a
ummulative dose range of 528-3465 mJ/cm2 (Ta-
le 2). Treatment interruptions or ommissions were
ue to transplantation-related adverse events and were
ot directly related to UV-B.
oxicity and Outcome
Myeloid engraftment was rapid (Table 3). Neu-
rophil (500/L) and platelet (20 000/l) recov-
ries occurred at medians of 13 days (range, 12-17)
nd 6.5 days (range, 1-35), respectively. One patient
eveloped hepatic venooclusive disease, and 1 had
rade IV hepato toxicity. Grade III infections were
een in 5 patients and 2 died from sepsis. Three
able 1. Patient and Graft Characteristics*
Patient No. Age Gender Diagnosis
1 59 F Myelofibrosis/AML
2 32 F Hodgkin disease
3 60 M Multiple myeloma
4 45 F Relapsed NHL
5 64 M Hodgkin disease
6 65 M Multiple myeloma
7 46 F Relapsed NHL
8 51 F AML (del5q)
AML indicates acute myeloid leukemia; NHL, non-Hodgkin lymph
MUD, matched unrelated donor graft; HDAC, high-dose cytar
able 2. Dermatologic Features and UV-B Therapy
Patient No.
Initial Dose
(mJ/cm2)
No. of UV-B
sessions
Total Dose
(mJ/cm2)
1 60 8 528 Sl
2 55 12 1491 M
3 80 10 1705 Sl
4 100 14 2000 Sl
5 220 12 3465 Sl
6 220 14 3260 Sl
7 75 13 1785 Sl
8 250 11 3000 Slight er
68atients had evidence of cytomegalovirus infection, 1
ad fungemia with Candida tropicalis, and 1 had zygo-
ycosis. Three patients developed grade III pulmonary
oxicity, and 1 developed bronchiolitis obliterans.
wo patients had grade III and 1 had grade IV renal
oxicity. One patient had secondary engraftment fail-
re 3 months after transplantation that was salvaged
y infusion of a single unit of umbilical cord blood
fter a second nonmyeloablative conditioning regi-
en. Another patient had mixed chimerism at day
00. This patient later relapsed.
Seven of 8 patients developed severe acute
VHD, grades III (n 5) and IV (n 2). Six had skin
nvolvement, 5 had gastrointestinal involvement, and
had liver involvement. Four patients died, 2 from
epsis, 1 from acute GVHD, and 1 from chronic
VHD. Four patients are alive (130-287 days), 3 with
xtensive chronic GVHD. All pretransplantation skin
iopsies were normal. Effects of UV-B therapy on the
oncentration of epidermal CD1a Langerhans cells
ere examined at baseline and on T-0 skin specimens
rom 4 patients (Figure 1). UV-B phototherapy re-
ulted in a decrease in CD1a epidermal Langerhans
ells in all 4 patients, although these cells were still
Previous Therapy
Graft
Source
CD34
(106/kg)
CD3
(108/kg)
halidomide MRD 4.5 3.2
obilization failure MUD 12.0 4.2
uto SCT MRD 5.4 4.4
uto SCT MUD 1.8 1.3
obilization failure MRD 3.6 3.3
uto SCT MRD 4.3 2.0
uto SCT MRD 6.7 2.0
3, HDAC MUD 16.2 3.5
CT, stem cell transplantation; MRD, matched related donor graft;
Toxicity Skin Biopsy after Transplant
ythema and
ness
Dermal edema and neutrophilic/macrophage
infiltrates, no GVHD
Chronic spongiotic dermatitis, ie,
erythrodermic, chronic drug eruption,
no GVHD
ptomatic burn Mild spongiotic and urticarial dermatitis
ythema Mild subacute spongiotic dermatitis,
consistent with drug eruption
GVHD grade III
ythema Early GVHD, spongiotic, and urticarial
reaction, consistent with drug eruption
ythema
ythema
ythema Mild folliculitisT
M
A
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M
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A
7
oma; SSkin
ight er
tender
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ight er
ight er
ight er
ight er
ight erythema Mild perivascular dermatitis
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Betectable at the time of stem cell infusion. Post-
ransplantation skin biopsies obtained upon suspicion
f GVHD showed mainly nonspeciﬁc inﬂammatory
eactions typical of early GVHD. In some of these
atients, repeat biopsies at later time points conﬁrmed
he diagnosis of GVHD.
ISCUSSION
We investigated the feasibility of incorporating
arrowband UV-B therapy to reduced-intensity con-
itioning therapy for allogeneic stem cell transplanta-
ion in an attempt to prevent engraftment failure and
ttenuate or decrease GVHD. By the Simon MinMax
-stage design, we terminated the study after 7 of the
rst 8 patients who were treated in this fashion devel-
ped grade III-IV acute GVHD (87.5%, 95% conﬁ-
ence interval, 53-98) and all 4 at-risk patients devel-
ped extensive chronic GVHD. This rate of severe
cute GVHD is higher than the rate of 15-50% re-
orted in various series of patients who underwent
onmyeloablative allogeneic stem cell transplantation.
ased on this small pilot trial, we cannot determine
hether the GVHD risk is actually worse than the
onditioning regimens without UV-B; however, the
robability of missing a beneﬁcial effect of UV-B
herapy is 20%. Of the 4 surviving patients, 1 de-
eloped engraftment failure but this was later salvaged
y transplantation of single-unit umbilical cord blood
ransplantation after a second nonmyeloablative con-
itioning regimen. The 3 remaining patients had ex-
ensive chronic GVHD. One patient later died with
elapsed disease.
Our ﬁndings are somewhat surprising because
arrowband UV-B phototherapy has been associated
ith T-cell unresponsiveness to alloantigens, inacti-
ation of antigen-presenting cells, depletion of Lang-
rhans cells from the epidermis, and migration of
ermal dendritic cells to draining lymph nodes
13,14]. Previous in vivo human primary immuniza-
ion studies have shown that immune tolerance to new
ntigens through UV-exposed skin of normal human
ubjects induce unresponsiveness and, in a subset, im-
able 3. Transplant Outcomes*
atient No. Acute GVHD Onset and Grade Chron
1 T63, G III Skin Ext
2 None Ext
3 T29, G IV skin, G I, Lv NA
4 T76, G III skin, G I Ext
5 T28, G IV skin, G I NA
6 T48, G III skin, G I NA
7 T42, G III, G I Ext
8 T33, G III skin Non
Lv indicates liver; NA, not applicable.une tolerance to these antigens upon subsequent t
B & M Tttempts to immunize with the same antigen through
ormal unexposed skin [15]. Further, transfusions of
V-B-irradiated peripheral blood mononuclear cells
ere asscociated with tolerance to major histocompat-
bility complex antigens [16,17]. Perhaps the timing
nd type of UV therapy we used induced an opposite
ffect by priming infused T cells in a cytokine-rich
kin microenvironment and initiated a cascade of im-
une events that culminated in severe GVHD.
As we expected, we found a rapid decrease in the
oncentration of Langerhans cells in the epidermis of
atients who underwent UV-B phototherapy in prepera-
ion for allogeneic transplantation. However, at the
ime of stem cell infusion, there were still detectable
ost Langerhans cells in the skin and we continued the
V-B therapy for another month. In a murine trans-
lantation model, depletion of host Langerhans cells
efore transplantation of donor alloreactive T cells pre-
ented skin GVHD [18]. Infusion of donor T cells to
himeric mice with persistent host Langerhans cells
esulted in skin GVHD. Mice with donor-type Lang-
rhans cells were protected. Although it is not possible
o directly extrapolate these ﬁndings to humans, we
peculate that, in our study, host Langerhans cell
epletion might have been incomplete or that UV-B
hototherapy after stem cell infusion might have de-
reased engraftment of donor Langerhans cells.
UV-B is less effective then psoralen-based photo-
herapy in the treatment of GVHD. This may be due
o greater penetration into the skin of the longer
avelengths of UV-A compared with UV-B, thus
ielding greater intralesional apoptosis of T cells. The
igh incidence of GVHD in our study also may be the
esult of a nonselective effective of UV-B on cells,
hereas psoralen–UV-A selects for T cells [19,20].
owever, UV-B phototherapy was found to be useful
n treatment of intraoral and cutaneous lichenoid
hronic GVHD [21]. The different mechanisms of
cute and chronic GVHD may be the explanation for
he unfavorable result in our study.
The optimal UV-B dose for immunosuppression
s not known. In vitro, lymphocytes were shown to be
ore sensitive to 33 J of UV-B compared with hema-
D Chimerism Status (Cause of Death)
Donor Died T216 (chronic GVHD)
Donor Alive T287
Donor Died T95 (acute GVHD)
Donor Relpsed T116, alive T182
Donor Died T73 (sepsis)
Donor Relpsed T92, died T133 (sepsis)
Mixed Alive T127
Recipient Alive T130ic GVH
ensive
ensive
ensive
ensive
eopietic progenitors [14]. In an animal model, the
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6ptimal dose found to suppress GVHD was 100 J/m2
rom a 290- to 320-nm light source [8]. At this dose,
he rate of bone marrow engraftment was impaired
ith 72% marrow cell cellularity at 2 weeks and de-
reased to 48% after 200 J/m2. Extrapolation of the
ndings from mice to humans has been difﬁcult be-
ause the large doses employed, 180 kJ/cm2, are as
uch as 400 times the minimal phototoxic UV-B dose
n untanned white skin. In humans, UV-B dosing that
s required to generate immunosuppression with
single exposure is approximately 2 MED, whereas
ull-spectrum simulated solar radiation requires 1
ED; thus, the dosing in this study may have been
nsufﬁcient [22]. The dosing employed in the present
tudy may also have been insufﬁcient to generate
olerogenic macrophages in the skin and draining
ymph nodes, which also requires a more inﬂamma-
ory dose than used here [23,24]. However, giving
igniﬁcant, whole-body, erythematous, clinically symp-
omatic sunburns would be impractical and poorly
olerated at the doses required to generate these
olerogenic macrophages.
Despite lower treatment-related mortality associated
ith decreased intensity protocols compared with con-
entional myleoablative protocols for allogeneic transpl-
atation, GVHD remains the major cause of morbidity
nd mortality for many patients [10]. In this report, the
ighest toxicity occured soon after transplantation, sug-
esting a direct negative effect of UV-B therapy on acute
VHD. Acute GVHD induction is divided in 3 phases
nd the conditioning regimen is responsible for the ﬁrst
hase by damaging intestinal mucosa and liver host cells,
eading to activation and release of inﬂammatory cyto-
ines (tumor necrosis factor 	, interferon 
, interleukin
) and upregulation of major histocompatability complex
ntigens and enhancing their recognation by donor T
ells [25,26]. Although a nonmyeloablative regimen was
pplied in our study, addition of UV-B might have in-
reased the cytokine secretion in skin and initiated the
VHD cascade.
In conclusion, peritransplant UV-B therapy using
he standard minimally erythemogenic dosing is det-
imental to the outcome of nonmyeloablative alloge-
eic stem cell transplantation. It is unclear how UV-B
ay have altered skin and systemic cytokine and im-
une cell compositions in the host that led to in-
reased GVHD and mortality. It is possible that the
V-B doses delivered were insufﬁcient or that the
chedule of UV-B was suboptimal. Clinical research
trategies that focus on UV-B phototherapy only be-
ore stem cell infusion with a goal of depleting skin
angerhans cells may yield different results. Although
ther phototherapeutic modalities and schedules may
e effective against GVHD, extended UV-B therapy
hould not be used during early phases of decreased
onditioning allogeneic transplantation. 1
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